Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals is a Melbourne-based specialty pharmaceutical company that develops and commercialises afamelanotide-based treatments, led by SCENESSE, the first FDA- and EMA-approved systemic photoprotective drug for adult EPP patients, distributed via accredited Expert Centres globally.
- Company typePublic
- Founded2005
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Clinuvel Pharmaceuticals does
Clinuvel Pharmaceuticals Limited (ASX: CUV) is a Melbourne-headquartered specialty pharmaceutical group developing and commercialising treatments for severe skin and central nervous system disorders with high unmet need. The company's platform is built on synthetic analogues of alpha-melanocyte stimulating hormone (α-MSH), with afamelanotide as its lead asset. SCENESSE (afamelanotide 16mg) is a subcutaneous controlled-release implant and the first systemic photoprotective drug approved by both the EMA (2014) and FDA (2019) for the prevention of phototoxicity in adult erythropoietic protoporphyria (EPP) patients — a rare metabolic disorder affecting roughly 10,000 people globally.
The product portfolio extends SCENESSE's reach through PRÉNUMBRA, a liquid injectable formulation targeting acute indications including arterial ischaemic stroke; NEURACTHEL (ACTH) for commercial supply in multiple dosage forms; CUV9900, an α-MSH analogue being evaluated for topical skin-protection applications; and CYACÊLLE, a 2023-launched PhotoCosmetic line offering tinted SPF50+ with broad UVA/UVB/HEV protection. Research and peptide-formulation work is concentrated in the wholly-owned VALLAURIX RD&I Centre in Singapore Science Park II, supported by the Singapore Economic Development Board and targeting full commissioning in FY2028.
CLINUVEL operates a controlled, specialty-pharmacy-style distribution model in which SCENESSE is dispensed only through accredited EPP Expert Centres and Specialty Centers in Europe, the UK, Switzerland, Israel, the USA (with a five-year US Department of Veterans Affairs contract running through July 2028), Canada via a Health Canada Special Access Program, and Australia. Pricing is negotiated through government reimbursement schemes, hospital procurement, and specialty pharmacy channels and is not publicly disclosed. The company generated AUD 36.8 million in H1 2026 revenue (up 4% year-over-year), has recorded eight consecutive years of profitability, holds approximately AUD 233 million in cash, and operates debt-free.
Clinuvel Pharmaceuticals firmographics
Firmographics- Name
- Clinuvel Pharmaceuticals
- Legal name
- CLINUVEL PHARMACEUTICALS LIMITED
- Website
- https://clinuvel.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Clinuvel Pharmaceuticals is a Melbourne-based specialty pharmaceutical company that develops and commercialises afamelanotide-based treatments, led by SCENESSE, the first FDA- and EMA-approved systemic photoprotective drug for adult EPP patients, distributed via accredited Expert Centres globally.
- Ownership category
- akta.pro rank
Clinuvel Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
- akta.pro secondary industries
- Professional/Backbar Skincare (Esthetician & Spa Use) (CRABAAAK), Acne & Congestion Treatments (HSALADAB)
Keywords
Where Clinuvel Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices7 records
Markets served
Clinuvel Pharmaceuticals business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales (SCENESSE): CLINUVEL generates revenue primarily from commercial sales of SCENESSE (afamelanotide 16mg) which is approved in Europe (since June 2016), USA (since April 2020), Israel, and Australia. The product is distributed through a controlled, specialty-pharmacy-style channel via accredited Expert Centres. Revenue grew 4% to AUD 36.8 million in H1 2026, marking the highest first-half sales in company history. The company has recorded eight consecutive years of annual profit.
- PhotoCosmetic Product Sales (CYACÊLLE): CLINUVEL launched its first PhotoCosmetic product, CYACÊLLE, in 2023 — a polychromatic tinted SPF50+ sunscreen providing triple light protection (UVA, UVB, HEV). The company is expanding its PhotoCosmetic portfolio targeting the general population with luxury skincare solutions.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Clinuvel Pharmaceuticals product offering
Product offeringCore offering
Clinuvel is a global specialty biopharmaceutical company that develops and commercialises treatments based on melanocortin peptide technology for patients with severe skin and brain disorders. Its lead product SCENESSE® (afamelanotide 16mg) is the first systemic photoprotective drug approved by both EMA and FDA for adult erythropoietic protoporphyria (EPP) patients, complemented by PRÉNUMBRA® (injectable), NEURACTHEL® (ACTH), CUV9900 α-MSH analogue, and the CYACÊLLE PhotoCosmetic skincare line.
Product overview
CLINUVEL Pharmaceuticals operates as a global specialty pharmaceutical group focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening acute disorders. The company's core portfolio includes SCENESSE® (afamelanotide 16mg), the world's first systemic photoprotective drug approved for erythropoietic protoporphyria (EPP); PRÉNUMBRA®, a liquid injectable formulation of afamelanotide for acute disorders including stroke; NEURACTHEL® (ACTH) for patients needing treatment; CUV9900 as an α-MSH analogue for skin protection; and the PhotoCosmetic line CYACÊLLE featuring tinted SPF50+ with polychromatic photoprotection. CLINUVEL also develops AI-driven technology like the Vitiligo Visual Algorithm for clinical assessment.
Differentiator
Problem solved
Functional benefit
Brands
- SCENESSE®: Afamelanotide 16mg - first systemic photoprotective drug approved by EMA and FDA for erythropoietic protoporphyria (EPP)
- PRÉNUMBRA®
- NEURACTHEL®
- CUV9900
- CYACÊLLE
- VALLAURIX
Products and services
- SCENESSE® (afamelanotide 16mg) Proprietary first-in-class photoprotective drug and the world's first systemic photoprotective therapy. Subcutaneous controlled-release implant of afamelanotide approved in Europe, USA, Israel, and Australia for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
- PRÉNUMBRA® Liquid (non-solid) injectable formulation of afamelanotide designed for flexible dose administration by a healthcare professional for acute and systemic diseases including stroke, acting as a vasoactive drug to counteract fluid formation in tissues.
- NEURACTHEL® (ACTH) Adrenocorticotropic hormone (ACTH) drug substance manufactured to cGMP standard, sourced from a strategic partner, commercialised by CLINUVEL in multiple dosage forms for patients in need of medical treatment.
- CUV9900 α-MSH analogue being investigated by CLINUVEL as a skin protectant; intended to be launched in various new formulations for topical applications.
- CYACÊLLE PhotoCosmetic Product Line PhotoCosmetic skincare product line featuring polychromatic solar protection from UVA, UVB, and HEV light; first product is a tinted SPF50+ offering triple-light protection and engineered to optimise skin longevity with DNA defence-and-repair technology.
Quantifiable outcome
- Sustained repigmentation in vitiligo patients with darker skin types (Fitzpatrick IV–VI) maintained up to six months after treatment withdrawal
- +3 more outcomes
Companies that use Clinuvel Pharmaceuticals
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Clinuvel Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature6 records
Clinuvel Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor and core.
- Skin of Color Society (SOCS)minorCLINUVEL participated in the Skin of Color Society's 22nd Annual Scientific Symposium held in conjunction with the AAD Annual Meeting in March 2026 in Denver, Colorado, convening nearly 500 attendees from 13 countries. The symposium featured scientific presentations and panels by dermatology experts including former U.S. Surgeon General Dr. Regina Benjamin.
- Singapore Economic Development Board (EDB)coreThe Singapore Economic Development Board supported CLINUVEL's strategic expansion of its VALLAURIX RD&I Centre in Singapore, which focuses on developing advanced long-acting peptide formulations and comprehensive scientific capabilities, targeting full commissioning in FY2028.
- Vitiligo Expert Panel (4 leading global vitiligo experts)coreCLINUVEL entered a formal collaboration with four of the world's leading vitiligo experts, who support clinical and scientific work and provide advice on the Company's late-stage development of and path to market for SCENESSE (afamelanotide) in vitiligo. This panel includes Dr Pearl Grimes among others.
- US Department of Veterans Affairs (VA)coreCLINUVEL was awarded a five-year contract by the US Department of Veterans Affairs to supply SCENESSE (afamelanotide) for adult erythropoietic protoporphyria (EPP) patients. The contract enables any adult EPP patient covered by the VA healthcare program to receive SCENESSE treatment at all VA facilities until July 2028.
- Health Canada (Special Access Program)minorFirst Canadian EPP patient received SCENESSE treatment under a Health Canada-approved Special Access Program (SAP) in May 2023, enabling access for Canadian patients before formal market authorisation.
- HK Winhealth Pharma Group Co. LimitedcoreCLINUVEL announced a partnership with HK Winhealth Pharma Group Co. Limited in China in April 2020 for the distribution of SCENESSE (afamelanotide) in China. This extends the commercial reach of CLINUVEL's lead product into the Asia-Pacific region.
- Strategic ACTH SupplierminorCLINUVEL has a commercial agreement with one of its strategic partners for the scaled supply of adrenocorticotropic hormone (ACTH) drug substance to cGMP standard. CLINUVEL will commercialise NEURACTHEL in multiple dosage forms.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
Clinuvel Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Incyte Corporation: Incyte commercializes Opzelura (ruxolitinib cream), the first FDA-approved repigmentation therapy for non-segmental vitiligo, and competes directly with CLINUVEL's vitiligo program. As a dermatology-focused commercial player, Incyte is the most direct competitive threat in CLINUVEL's largest near-term pipeline indication.
- Swedish Orphan Biovitrum (Sobi): Sobi is a European-based specialty biopharma focused on rare diseases including dermatology and immunology. Its portfolio of orphan-designated products distributed via specialty channels directly parallels CLINUVEL's commercial model in EPP and planned vitiligo/VP launches.
- BioMarin Pharmaceutical: BioMarin is a global rare disease biopharmaceutical company with a portfolio of approved specialty products and a late-stage pipeline. It compares to CLINUVEL through its ultra-rare-disease focus, controlled specialty distribution, and reliance on breakthrough-designated products to fund pipeline expansion.
- Alnylam Pharmaceuticals: Alnylam is a US specialty biopharmaceutical company developing RNA interference therapeutics for rare diseases. Like CLINUVEL, it operates a focused rare-disease commercial model with strong cash flow from approved products and pipeline expansion into additional indications, making it a directly comparable business model peer.
Broad incumbents
- Recordati Rare Diseases: Recordati operates a specialty pharmaceutical business with a dedicated rare diseases unit that markets treatments for ultra-rare conditions via specialty distribution channels in Europe and globally. It is comparable to CLINUVEL in commercial model and orphan-disease focus.
- Jazz Pharmaceuticals: Jazz is a specialty biopharmaceutical company that commercializes treatments for serious rare and central nervous system diseases. Its portfolio of orphan-designated CNS and rare-disease products aligns with CLINUVEL's expansion into stroke (AIS) and other CNS indications.
- Galderma: Galderma is a global dermatology-focused specialty company offering prescription, aesthetic, and consumer skincare products. While broader than CLINUVEL, its dermatology focus and consumer skincare extension (via Cetaphil and prescription brands) make it a relevant comparable for the combined pharmaceutical/PhotoCosmetic strategy.
- Vertex Pharmaceuticals: Vertex is a large-cap specialty biopharma with a focus on serious diseases and a track record of capital-efficient rare-disease commercialization. It serves as a benchmark for what CLINUVEL could scale toward as its vitiligo and pipeline indications mature.
Emerging players
- Arcutis Biotherapeutics: Arcutis is a US dermatology-focused specialty pharma commercializing topical treatments for inflammatory skin conditions. Its specialist-focused sales model and dermatology pipeline make it an emerging comparator as CLINUVEL enters adjacent dermatology indications.
- Aclaris Therapeutics: Aclaris is a clinical-stage dermatology company developing treatments for immuno-inflammatory skin diseases. Its focus on vitiligo and immune-mediated dermatology overlaps with CLINUVEL's vitiligo and VP programs, positioning it as a potential emerging peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Clinuvel Pharmaceuticals social profiles
Digital presenceClinuvel Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clinuvel Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles11 records
Clinuvel Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Clinuvel Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clinuvel Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clinuvel Pharmaceuticals
What does Clinuvel Pharmaceuticals do?
Clinuvel is a global specialty biopharmaceutical company that develops and commercialises treatments based on melanocortin peptide technology for patients with severe skin and brain disorders. Its lead product SCENESSE® (afamelanotide 16mg) is the first systemic photoprotective drug approved by both EMA and FDA for adult erythropoietic protoporphyria (EPP) patients, complemented by PRÉNUMBRA® (injectable), NEURACTHEL® (ACTH), CUV9900 α-MSH analogue, and the CYACÊLLE PhotoCosmetic skincare line.
Is Clinuvel Pharmaceuticals a public or private company?
Clinuvel Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Clinuvel Pharmaceuticals founded?
Clinuvel Pharmaceuticals was founded in 2005. It employs 11 to 50 people.
Where is Clinuvel Pharmaceuticals based?
Clinuvel Pharmaceuticals is headquartered in Melbourne, Australia, in the Oceania region.
How does Clinuvel Pharmaceuticals make money?
Two revenue lines are on record. Pharmaceutical Product Sales (SCENESSE) is the primary driver. The others are photoCosmetic Product Sales (CYACÊLLE).
Who are Clinuvel Pharmaceuticals's main competitors?
Direct peers on record are Incyte Corporation, Swedish Orphan Biovitrum (Sobi), BioMarin Pharmaceutical and Alnylam Pharmaceuticals. Broad incumbents are Recordati Rare Diseases, Jazz Pharmaceuticals, Galderma and Vertex Pharmaceuticals. Emerging players are Arcutis Biotherapeutics and Aclaris Therapeutics.
Does Clinuvel Pharmaceuticals have an API?
No public API is recorded for Clinuvel Pharmaceuticals.
What industry is Clinuvel Pharmaceuticals in?
Clinuvel Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is CRABAAAF, Dermocosmetics & Medical-Grade Skincare, with a secondary code of CRABAAAK, Professional/Backbar Skincare (Esthetician & Spa Use). Its NAICS code is 325414 and its SIC code is 2844.